NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Axcynsis Therapeutics

Axcynsis Therapeutics

Private
SingaporeHealthcare & Life Scienceshttps://axcynsis.com/

Last Round

VC Round

Oct 1, 2024

Total Funding Raised

$15M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Axcynsis Therapeutics is a biotechnology company that develops antibody-drug conjugate (ADC) therapies designed for treating cancer.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologydrug discoveryantibody-drug conjugatesADCbiopharmaceuticaltherapeutic pipelinesite-specific conjugationantibody engineeringpre-clinical researchbiotech licensingdrug developmentsmall moleculebiologic therapeuticsdrug discovery platformpharma R&D

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Axcynsis Therapeutics Comparables

Compare Axcynsis Therapeutics with similar companies based on industry and business-model similarity.

Axcynsis Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
DotBio
82%
Albatroz Therapeutics
79%
Adcytherix
78%

Axcynsis Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundOct 1, 2024
SeedMay 4, 2022

Key People

Founding team and executive leadership

Zou Bin

Founder And CEO

Founding Team

Axcynsis Therapeutics Investors

Notable investors and investment history

Axcynsis Therapeutics investors
InvestorRounds
Trinity Innovation FundSeed, VC Round

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 15, 2026

    Monthly visitors increased 188% MoM, reaching 916.

  • Apr 21, 2025

    Developing new Antibody Drug Conjugate (ADC) therapies.

Axcynsis Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Axcynsis Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Axcynsis Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersSingapore
Employee Range6
Year Founded2022
Last FundingOct 1, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.